HC Wainwright Issues Positive Estimate for Acelyrin Earnings

Acelyrin, Inc. (NASDAQ:SLRN - Free Report) - HC Wainwright increased their FY2024 earnings estimates for shares of Acelyrin in a report released on Thursday, November 14th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($2.43) per share for the year, up from their previous estimate of ($3.35). HC Wainwright has a "Neutral" rating and a $8.00 price objective on the stock. The consensus estimate for Acelyrin's current full-year earnings is ($2.90) per share. HC Wainwright also issued estimates for Acelyrin's Q4 2024 earnings at ($0.72) EPS, FY2025 earnings at ($2.17) EPS, FY2026 earnings at ($2.56) EPS, FY2027 earnings at ($2.07) EPS and FY2028 earnings at ($1.30) EPS.

Several other research analysts have also commented on the stock. Morgan Stanley cut their price target on shares of Acelyrin from $13.00 to $6.00 and set an "equal weight" rating on the stock in a report on Monday, August 19th. Piper Sandler reduced their target price on shares of Acelyrin from $68.00 to $20.00 and set an "overweight" rating on the stock in a report on Wednesday, August 14th. Finally, Wells Fargo & Company upped their price target on shares of Acelyrin from $13.00 to $15.00 and gave the stock an "overweight" rating in a research report on Wednesday, October 16th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $11.50.

Acelyrin Stock Down 0.9 %

Shares of NASDAQ SLRN traded down $0.04 during trading on Monday, hitting $4.65. 614,182 shares of the company traded hands, compared to its average volume of 1,025,196. The firm has a market capitalization of $466.52 million, a P/E ratio of -1.91 and a beta of 1.98. The company has a 50-day moving average price of $5.41 and a 200-day moving average price of $5.03. Acelyrin has a 1 year low of $3.36 and a 1 year high of $9.00.

Institutional Investors Weigh In On Acelyrin

A number of large investors have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. grew its stake in shares of Acelyrin by 118.0% during the first quarter. Ameritas Investment Partners Inc. now owns 7,243 shares of the company's stock valued at $49,000 after acquiring an additional 3,921 shares in the last quarter. HighTower Advisors LLC acquired a new stake in Acelyrin during the 3rd quarter valued at approximately $50,000. Principal Financial Group Inc. purchased a new stake in Acelyrin during the 2nd quarter worth approximately $49,000. SG Americas Securities LLC acquired a new position in shares of Acelyrin in the 2nd quarter valued at approximately $51,000. Finally, Nisa Investment Advisors LLC boosted its stake in shares of Acelyrin by 58,570.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 14,081 shares of the company's stock valued at $62,000 after buying an additional 14,057 shares during the last quarter. 87.31% of the stock is owned by institutional investors and hedge funds.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.